A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 45.65M shares outstanding
USA clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform.
The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis.
Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Cathrine Jooste
Chief Commercial Officer & North America Regional Director
Óscar Velásquez
Managing Director of Atento Colombia
Employees
44
Country
US
Sector
Healthcare
Website
attovia.com
Loading congressional disclosures…
based on 45.65M shares outstanding
US30d Avg
487.15K
60d Avg
346.86K
90d Avg
451.83K
